Robert Pyo, MD
Interventional Cardiology · Jamaica, NYNPI 1417997867
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Boston Scientific at 37.1% of the total. Reporting peaked in 2024 at $18,195 and has fallen 69.2% since, to $5,609 in 2025.
Across 313 payments — averaging $193.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$23K
- Abiomed$16K
- Medtronic$9K
- Abbott$8K
- Shockwave Medical, Inc$1K
- Spectrawave, Inc$1K
- plus $3K from 24 others
Across 89 payments — averaging $2215.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$156K
- Medtronic$42K
What the payments were for
- Consulting fees$3,4756%
- Speaking & faculty fees$31,01351%
- Travel & lodging$6,01810%
- Food & beverage$20,12533%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 57 | $22,518 |
| Abiomed | 45 | $16,136 |
| Medtronic(2 entities) | 72 | $8,559 |
| Abbott | 57 | $7,691 |
| Shockwave Medical, Inc | 17 | $1,200 |
| Spectrawave, Inc | 9 | $1,104 |
| Edwards Lifesciences | 7 | $724 |
| Saranas, Inc. | 6 | $459 |
| Philips North America LLC | 4 | $449 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $320 |
| Kestra Medical Technology Services, Inc. | 2 | $274 |
| Recor Medical Inc | 2 | $212 |
| Terumo Medical Corporation | 2 | $195 |
| Endotronix, Inc. | 1 | $180 |
| Collaborative Care Diagnostics, LLC | 2 | $131 |
| Cardinal Health 200 LLC | 4 | $89 |
| Penumbra, Inc. | 4 | $57 |
| Chiesi USA, Inc. | 3 | $55 |
| Amgen | 1 | $45 |
| Novartis | 2 | $40 |
| Johnson & Johnson | 2 | $33 |
| Argon Medical Devices, Inc. | 1 | $26 |
| Acist Medical Systems, Inc. | 1 | $24 |
| Vifor Pharma, Inc. | 1 | $23 |
| Procyrion, Inc. | 1 | $20 |
| Pfizer | 1 | $20 |
| Cardiva Medical, Inc. | 1 | $14 |
| Portola Pharmaceuticals, LLC | 1 | $14 |
| Teleflex LLC | 1 | $12 |
| Cardiovascular Systems Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$15,206
- CoreValve Evolut$3,473
- DRAGONFLY OPSTAR$2,875
- COREVALVE EVOLUT R$1,887
- AVVIGO Guidance System$1,036
- HyperVue Imaging System$937
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$922
- Mitra Clip system$811
- Starlight Imaging Catheter$700
- SYMPLICITY G3$660
- MitraClip System$612
- AVVIGO$600
- MitraClip$420
- Resolute$406
- TRICLIP$393
- ONYX FRONTIER$316
- HawkOne$300
- (6574) Coronary Other$300
- GENERAL - THERAPIES$271
- OPTICROSS$187
How this compares
$60,631 in reported general payments places this provider in the 80th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 22 | $28,262 |
| EliquisApixaban | 22 | $23,347 |
| JardianceEmpagliflozin | 16 | $22,365 |
| BrilintaTicagrelor | 14 | $17,876 |
| Ezetimibe | 79 | $3,390 |
| Atorvastatin Calcium | 126 | $1,200 |
| Metoprolol Succinate | 78 | $807 |
| Carvedilol | 34 | $309 |
| ClopidogrelClopidogrel Bisulfate | 37 | $200 |
| Lisinopril | 27 | $199 |
| Spironolactone | 22 | $143 |
| Amlodipine Besylate | 29 | $127 |
| Furosemide | 15 | $94 |
| Hydrochlorothiazide | 18 | $87 |
| Losartan Potassium | 14 | $82 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $40 | $28,26222 claims |
| PfizerEliquis | $20 | $23,34722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in Jamaica
- Sahil ParikhNew York$1.6M
- Deepak BhattNew York$1.6M
- Martin LeonNew York$1.5M
- Evan ShlofmitzRoslyn$951K
- Mohamed Azeem LatibBronx$816K
- Yili HuangElmhurst$699K
- Ali HaiderAstoria$492K
- Sripal BangaloreNew York$482K
- Ajay KirtaneNew York$462K
- David CohenRoslyn$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.